As whole-genome sequencing becomes more common in the clinic, doctors may be facing the consequences of the technological shift, says this article at Slate from Future Tense's Gary Marchant and Rachel Lindor. Whole-genome sequencing opens up a number of liabilities for physicians, Marchant and Lindor say.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.